Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers a nonrandomized clinical trial

Annals of Internal Medicine

Volumn 167, Issue 5, 2017, Pages 311-318

  Kattakuzhy, Sarah ^a   Gross, Chloe ^a   Emmanuel, Benjamin ^a   Teferi, Gebeyehu ^b   Jenkins, Veronica ^c   Silk, Rachel ^d   Akoth, Elizabeth ^a   Thomas, Aurielle ^d   Ahmed, Charisse ^d   Espinosa, Michelle ^a   Price, Angie ^a   Rosenthal, Elana ^a   Tang, Lydia ^a   Wilson, Eleanor ^a   Bentzen, Soren ^d   Masur, Henry ^d   Kottilil, Shyam ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Unity Health Care Walker Jones   (United States)

^c Family and Medical Counseling Service Inc   (United States)

^d Howard Hall 109D ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; OPIATE; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; AUTOPSY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRICT OF COLUMBIA; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GENERAL PRACTITIONER; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MIXED INFECTION; NURSE PRACTITIONER; OBSERVATIONAL STUDY; OPEN STUDY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMMUNITY CARE; COMPLICATION; GASTROENTEROLOGIST; HEPATITIS C, CHRONIC; INFECTIOUS DISEASE MEDICINE; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PHASE 4 CLINICAL TRIAL; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COMMUNITY HEALTH SERVICES; DISTRICT OF COLUMBIA; FEMALE; GASTROENTEROLOGISTS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE MEDICINE; LIVER CIRRHOSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NURSE PRACTITIONERS; PHYSICIANS, PRIMARY CARE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85028846309     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-0118     Document Type: Article

References (23)

1. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9:e101554. [PMID: 24988388] doi:10. 1371/journal. pone. 0101554
2. American Association of American Medical Colleges. 2015 State Physician Workforce Data Book. Washington, DC: American Association of American Medical Colleges; November 2015. Accessed at www. aamc. org/data/workforce/reports/442830/statedataandreports. html on 1 October 2016.
3. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2017. Accessed at www. hcvguidelines. org on 1 October 2016.
4. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-207. [PMID: 2163 1316] doi:10. 1056/NEJMoa1009370
5. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300. [PMID: 24737271] doi:10. 7326/M13-1133
6. World Health Organization; U. S. President's Emergency Plan for AIDS Relief; Joint United Nations Programme on HIV/AIDS. Task-Shifting: Rational Redistribution of Tasks among Health Workforce Teams: Global Recommendations and Guidelines. Geneva: World Health Organization; 2007.
7. Cheng W, Nazareth S, Flexman JP. Statewide hepatitis C model of care for rural and remote regions. J Gastroenterol Hepatol. 2015;30 Suppl 2:1-5. [PMID: 25641223] doi:10. 1111/jgh. 12863
8. Rossaro L, Torruellas C, Dhaliwal S, Botros J, Clark G, Li CS, et al. Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California. Dig Dis Sci. 2013;58:3620-5. [PMID: 24154637] doi:10. 1007 /s10620-013-2810-y
9. Tazawa J, Sakai Y, Kusano F, Nagayama K, Fujiwara H. Collaboration between hepatologists and primary care physicians in treating patients with chronic hepatitis C. J Rural Med. 2011;6:54-9. [PMID: 25648346] doi:10. 2185/jrm. 6. 54
10. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens. J Clin Gastroenterol. 2015;49:329-35. [PMID: 24667591] doi:10. 1097/MCG. 0000000000000124
11. Woodrell C, Weiss J, Branch A, Gardenier D, Krauskopf K, Kil N, et al. Primary care-based hepatitis C treatment outcomes with firstgeneration direct-acting agents. J Addict Med. 2015;9:405-10. [PMID: 26291545] doi:10. 1097/ADM. 0000000000000147
12. Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al; New Paradigm of HCV Therapy Meeting Participants. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20:745-60. [PMID: 24168254] doi:10. 1111/jvh. 12173
13. Kottilil S, Wright M, Polis MA, Masur H. Treatment of hepatitis C virus infection: is it time for the internist to take the reins Ann Intern Med. 2014;161:443-4. [PMID: 25222390] doi:10. 7326/M14-0741
14. Gilead Sciences. HARVONI U. S. full prescribing information. June 2016. Accessed at www. gilead. com/~/media/Files/pdfs/medicines /liver-disease/harvoni/harvoni-pi. pdf on 1 June 2017.
15. National Institute of Allergy and Infectious Diseases; National Institutes of Health; U. S. Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2. 0. 2013. Accessed at https://rsc. tech-res. com/docs/default-source/safety/daids-ae-grading-table- v2-nov2014. pdf on 1 October 2016.
16. District of Columbia Department of Health; HIV/AIDS, Hepatitis, STD, and TB Administration. Annual Epidemiology & Surveillance Report 2013. 2013. Accessed at https://doh. dc. gov/sites/default /files/dc/sites/doh/page-content/attachments/2013%20Annual%20 Report%20Final%20Edit. pdf on 1 October 2016.
17. Terrault ZS, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al; HCV-TARGET Study Group. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study [Abstract]. Presented at 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 13-17 November 2015. Abstract no. 94.
18. Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs national health care system. Gastroenterology. 2016;151:457-71. [PMID: 27267053] doi: 10. 1053/j. gastro. 2016. 05. 049
19. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859-61. [PMID: 23675657] doi:10. 1056/NEJMp1302973
20. Centers for Disease Control and Prevention. Viral hepatitis: hepatitis C. 2015. Accessed at www. cdc. gov/hepatitis/hcv on 1 October 2016.
21. U. S. Preventive Services Task Force. Hepatitis C: screening. 2015. Accessed at www. uspreventiveservicestaskforce. org/Page /Document/UpdateSummaryFinal/hepatitis-c-screening on 1 October 2016.
22. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV testing and linkage to care. 2017. Accessed at www. hcvguidelines. org/full-report/hcv-testing-and-linkage-care on 1 October 2016.
23. Weiss JJ, Johnson N, Licht CA, Krauskopf K, Nissenson-Glied K, Sigel K, et al. Initial validation of the psychosocial readiness evaluation and preparation for hepatitis C treatment (PREP-C) [Abstract]. Presented at International Conference on Viral Hepatitis 2012, New York, New York, 26-27 March 2012. Abstract no. 79354.